Daily Low-Dose Cialis

[widget]

I think at 50 years of age and a 499 ng/dL total testosterone blood level I would have suggested first:

1- Better sleep. Good sleep hygiene (going to bed before 10-11 pm, getting 7-8 hours of sleep, ensuring that you have no sleep apnea) can improve T levels.

2- Weight loss. If your BMI is over 26, losing weight may improve T level.

3- Ensuring that your blood drawn was done in the morning and under fasting conditions. Breakfast can decrease testosterone by 20 percent due to a spike in insulin.

4- Taking low dose Cialis daily. This has been proven to increase the testosterone-to-estradiol ratio.

5- Measuring your LH, FSH, TSH, free T3 and free T4. Low thyroid function mimics the symptoms of low T.

You obviously were not being dosed right since your total T never increased beyond baseline.

I do not know what dose of Clomid you took. Some men successfully get off TRT with a HPTA reset protocol but the 4-6 week process is usually not really fun.

A staggered combination of HCG, Clomid and Tamoxifen are used.

We can discuss that in more detail if you wish.

Nelson, not to hijack the thread but is there somewhere on this site where you've expanded more on the daily low-dose Cialis? I've never heard of that. Sounds interesting.

 

[CoastWatcher]

Nelson, not to hijack the thread but is there somewhere on this site where you've expanded more on the daily low-dose Cialis? I've never heard of that. Sounds interesting.

Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study.


http://www.ncbi.nlm.nih.gov/pubmed/16839328



CONCLUSIONS:

Sustained improvement in sexual function after 12 months of tadalafil administration is associated with increased T:E ratio mainly related to reduction of E levels. We hypothesize that androgen-estrogen cross-talk and possible inhibition of aromatase activity during chronic exposure to tadalafil might have a role in the regulation of erectile function.

 

[Nelson Vergel]

Efficacy and Safety of Daily Tadalafil in Men with Erectile Dysfunction Previously Unresponsive to On-demand Tadalafil

[h=2]The Journal of Sexual Medicine[/b]Volume 1, Issue 3, pages 292–300, November 2004



ABSTRACT
Objective.  To assess the efficacy and safety of daily tadalafil, a potent selective phosphodiesterase 5 inhibitor, for the treatment of erectile dysfunction (ED) in men previously unresponsive to on-demand tadalafil.

Materials and Methods.  A total of 112 men with a mean age of 63 (range 21–79) and moderate to severe ED of various aetiologies were treated with tadalafil, taken on a daily basis at flexible daily doses of 10 and 20 mg for 12 weeks. The three primary outcomes were changes from the pretreatment and on-demand tadalafil baseline in the erectile function domain of the International Index of Erectile Function and the proportion of yes responses to questions 2 and 3 of the Sexual Encounter Profile. Additional efficacy instruments included a Global Assessment Question administered at completion of the study.

Results.&#8194; Compared with pretreatment and on-demand tadalafil baseline, daily dosed tadalafil significantly enhanced all efficacy outcome variables. Patients receiving daily tadalafil (10 mg) experienced a significant mean improvement of 12.8 and 8.2 in the International Index of Erectile Function erectile function domain score from baseline (P < 0.001) and from on-demand tadalafil, respectively (P < 0.001). Fifty-eight percent of intercourse attempts (Sexual Encounter Profile question 3) were successfully completed (P < 0.001 vs. pretreatment baseline, P < 0.001 vs. on-demand tadalafil). Improved erections at end point were reported by 69% of men compared with 42% of men with on-demand tadalafil. Daily tadalafil was well tolerated with headache, dyspepsia, and facial flushing as the most frequent adverse events.

Conclusion.&#8194; Daily tadalafil (10/20 mg) was effective and well tolerated in this study population and is an effective salvage for previous on-demand tadalafil nonresponders.

 

[Nelson Vergel]

CIALIS for ED+BPH (erectile dysfunction + symptoms of benign prostatic hyperplasia)


Tadalafil is PDE5 inhibitor marketed in pill form for treating erectile dysfunction (ED) under the name Cialis, and under the name Adcirca for the treatment of pulmonary arterial hypertension. In October 2011 the U.S. Food and Drug Administration (FDA) approved Cialis for treating the signs and symptoms of benign prostatic hyperplasia (BPH) as well as a combination of BPH and erectile dysfunction (ED) when the conditions coincide. It initially was developed by the biotechnology company ICOS, and then again developed and marketed world-wide by Lilly ICOS, LLC, the joint venture of ICOS Corporation and Eli Lilly and Company. Cialis tablets, in 2.5 mg, 5 mg, 10 mg, and 20 mg doses, are yellow, film-coated, and almond-shaped. The approved dose for pulmonary arterial hypertension is 40 mg (two 20-mg tablets) once daily.
Tadalafil is also manufactured and sold under the name of Tadacip by the Indian pharmaceutical company Cipla in doses of 10 mg and 20 mg.
On November 21, 2003 the FDA approved tadalafil (as Cialis) for sale in the United States as the third ED prescription drug pill (after sildenafil citrate (Viagra) and vardenafil Hydrochloride (Levitra)). Like sildenafil and vardenafil, tadalafil is recommended as an 'as needed' medication. Cialis is the only one of the three that is also offered as a once-daily medication.

 

[Nelson Vergel]

Impact on Erectile Function and Sexual Quality of Life of
Couples: A Double-Blind, Randomized, Placebo-Controlled
Trial of Tadalafil Taken Once Daily